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AbstrAct
Objective We aimed to evaluate the limit of detection 
of high-sensitivity troponin (hs-cTn) and Thrombolysis In 
Myocardial Infarction (TIMI) score combination rule-out 
strategy suggested within the 2016 National Institute for 
Health and Care Excellence (NICE) Chest Pain of Recent 
Onset guidelines and establish the optimal TIMI score 
threshold for clinical use.
Methods A pooled analysis of adult patients presenting 
to the emergency department with chest pain and a 
non-ischaemic ECG, recruited into six prospective studies, 
from Australia, New Zealand and the UK. We evaluated 
the sensitivity of TIMI score thresholds from 0 to 2 
alongside hs-cTnT or hs-cTnI for the primary outcome of 
major adverse cardiac events within 30 days.
results Data were available for 3159 patients for 
hs-cTnT and 4532 for hs-cTnI, of these 376 (11.9%) 
and 445 (9.8%) had major adverse cardiac events, 
respectively. Using a TIMI score of 0, the sensitivity 
for the primary outcome was 99.5% (95% CI 98.1% 
to 99.9%) alongside hs-cTnT and 98.9% (97.4% to 
99.6%)%) alongside hs-cTnI, identifying 17.9% and 
21.0% of patients as low risk, respectively. For a TIMI 
score ≤1 sensitivity was 98.9% (97.3% to 99.7%)%) 
alongside hs-cTnT and 98.4% (96.8% to 99.4%)%) 
alongside hs-cTnI, identifying 28.1% and 35.7% as low 
risk, respectively. For TIMI≤2, meta-sensitivity was <98% 
with either assay.
conclusions Our findings support the rule-out strategy 
suggested by NICE. The TIMI score threshold suggested 
for clinical use is 0. The proportion of patients identified 
as low risk (18%–21%) and suitable for early discharge 
using this threshold may be sufficient to encourage 
change of practice.
trial registration numbers ADAPT 
observational study/IMPACT intervention trial 
ACTRN12611001069943. ADAPT-ADP randomised 
controlled trial ACTRN12610000766011. EDACS-
ADP randomised controlled trial 
ACTRN12613000745741. TRUST observational study 
ISRCTN no. 21109279.
IntrOductIOn
The 2016 update to the National Institute for 
Health and Care Excellence (NICE) CG95 
Chest Pain of Recent Onset guidelines proposes 
a step change in the use of biomarkers for the 
diagnosis of acute coronary syndrome (ACS).1 For 
the first time in the UK, a rule-out strategy using a 
single high-sensitivity cardiac troponin (hs-cTn) test 
taken at presentation to the emergency department 
(ED) is recommended. NICE suggest that clinicians
‘consider performing a hs-cTn test only at 
presentation to rule-out non-ST elevation myocardial 
infarction (NSTEMI) if the test is below the limit 
of detection (LoD)’ and ‘the patient is low-risk as 
indicated by a validated tool’.
Numerous observational studies have evaluated 
the limit of detection (LoD) (lowest analyte concen-
tration at which detection is feasible) of hs-cTn 
assays alone at presentation to ED.2–7 This cut-off 
concentration of the hs-cTnT assay, when combined 
with a non-ischaemic ECG, is potentially safe. In a 
meta-analysis of >9000 patients, pooled sensitivity 
for 30-day major adverse cardiac events (MACEs) 
was 98.0% (95% CI 94.7% to 99.3%).8
However, the strategy suggested by NICE 
mandates that a risk stratification tool is used along-
side the LoD cut-off on a single troponin sample 
to identify patients suitable for discharge after a 
single hs-cTn test. The Thrombolysis In Myocar-
dial Infarction (TIMI) score9 or the Global Registry 
of Acute Cardiac Events (GRACE) score10 are 
suggested for clinical use.1 The GRACE score has 
been shown to have limited efficacy in combination 
with presentation hs-cTn testing.11 Prior evaluations 
of the TIMI score in combination with hs-cTn assay 
results in ED patients with chest pain have demon-
strated that between 20% and 40% of patients will 
be low risk.11–13 Yet, these studies have incorporated 
cut-offs at the 99th percentile rather than the LoD 
and most have used serial hs-cTn sampling. Further-
more, NICE recommends that TIMI score thresh-
olds of 0–2 are applied to define a patient as low 
risk.1 This approach has not been validated; there-
fore, how best to apply the NICE recommendations 
in a clinical environment remains unknown.
The use of hs-cTn cut-offs between the LoD and 
the 99th percentile to maximise the proportion of 
patients suitable for discharge after a single hs-cTn 
result has also been explored.7 14 It may be possible 
that by incorporating the TIMI score with low 
cut-off concentrations of hs-cTn will increase the 
proportion of patients suitable for discharge after a 
single hs-cTn result.
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We aimed to validate the LoD and TIMI score combina-
tion strategy suggested by NICE, in prospectively recruited 
ED patients with suspected cardiac chest pain, using the two 
commercially available hs-cTn assays and establish which TIMI 
score cut-off should be implemented in clinical practice. In addi-
tion, we aimed to explore the safety and efficacy of low hs-cTn 
cut-offs above the LoD in combination with the TIMI score 
using simulation modelling.
MethOds
study design and participants
The study population consisted of eligible patients presenting to 
the ED with chest pain, recruited into six prospective studies, 
from three countries: the Brisbane, Australia, and Christchurch, 
New Zealand, cohorts of the Accelerated Diagnostic Protocol 
to Assess Patients with Chest Pain Symptoms Using Contem-
porary Troponins as the Only Biomarker (ADAPT) observa-
tional study,12 the Brisbane, Australia cohort of the  Improved 
Assessment of Chest pain Trial (IMPACT) intervention trial,15 
the Christchurch ADAPT-ADP randomised controlled trial,16 
the Christchurch Emergency Department of Chest Pain Score 
(EDACS-ADP) randomised controlled trial,13 and the Poole, 
UK, Triage Rule-out Using high-Sensitivity Troponin.(TRUST) 
observational study.5 Inclusion and exclusion criteria, assessment 
of ECG, preparation of samples and assays used for diagnosis of 
Acute Myocardial Infarction (AMI) have been reported in detail 
in each study.5 12 13 15 16 All patients recruited in the trials were 
eligible for enrolment if they presented with chest pain symptoms 
suggestive of cardiac ischaemia and investigation for ACS with 
serial biomarker tests was planned. Detailed exclusion criteria 
are included in the online supplementary material. Specific to 
this analysis, participants in whom hs-cTn results taken at presen-
tation to the ED were not available were excluded. In addition, 
patients with new onset ECG changes diagnostic of ischaemia 
(ST segment depression ≥1 mm or T-wave inversion consistent 
with ischaemia) were excluded. These patients are high-risk 
independent of hs-cTn results or TIMI score and therefore not 
suitable for early discharge.
Written informed consent was obtained from all patients and 
the study protocols were approved by the respective local ethics 
committees. Recruitment was undertaken from 1 November 
2007 to 1 January 2015.
clinical processes
All participants had laboratory troponin concentrations 
measured at presentation and at least 2 hours later. The assays in 
use for routine clinical care at the time of recruitment and serial 
testing time points are detailed in online supplementary table 
2. All clinical management was at the discretion of the treating 
clinician.
Laboratory measurement
Testing was undertaken using both commercially available hs-cTn 
(T and I) assays. One study (TRUST) used the Elecsys hs-cTnT 
assay (Roche, Basel, Switzerland) and one study (EDACS-ADP) 
used the Architect hs-cTnI assay (Abbott Diagnostics, Chicago, 
Illinois, USA) in routine clinical care (online supplemen-
tary table 2), where analysis was undertaken in real time. In 
remaining studies, research samples taken on presentation were 
centrifuged and serum stored frozen at ≤−70°C for later anal-
ysis. The LoD for hs-cTnT is 5 ng/L.17 For hs-cTnI, a range of 
1.2–1.9 ng/L for the LoD is quoted,17 we rounded this value 
to 2 ng/L as is common laboratory practice.18 Prior analysis of 
applying the LoD at 2 ng/L, rather than 1.2 ng/L, for hs-cTnI, has 
demonstrated an improved efficacy (patients eligible for early 
discharge; 25.6% vs 18.8%) but with a reduction in diagnostic 
sensitivity (99.0% vs 97.9%).7
Patient data and tIMI risk scores
Patient data were recorded according to standardised data collec-
tion forms using a published data dictionary.19 TIMI risk scores 
(box 1) were calculated from clinical data recorded by research 
staff. Follow-up events were monitored by dedicated research 
staff through a combination of telephone contact, corrobora-
tion by review of hospital online patient management systems 
and query to the national death registries at least 6 months after 
index presentation.
Outcomes
Given the focus of NICE Guideline CG95 on the rule-out of 
ACS, we deemed that the most appropriate primary outcome for 
this analysis was the sensitivity (as a measure of safety) of each 
strategy for MACE occurring within 30 days of hospital atten-
dance. MACE included death due to ischaemic heart disease, 
cardiac arrest, unplanned symptom-induced revascularisation, 
cardiogenic shock, ventricular arrhythmia, high-degree atrio-
ventricular block needing intervention and AMI. This outcome 
was adjudicated by researchers with knowledge of the troponin 
assay results in clinical use, ECGs and all other clinical infor-
mation available up to 30 days after presentation. Methods for 
the adjudication of MACE by study site are detailed in online 
supplementary table 1.
The presence of AMI was defined according to the Third 
Universal Definition, which states that a rise and/or fall in 
troponin, with at least one value above the 99th percentile value 
in a patient with ischaemic symptoms or signs, would satisfy the 
diagnosis.20 AMI was adjudicated using presentation and late 
troponin results, according to assays in use at each institution at 
the time of recruitment (online supplementary table 2).
The secondary outcome was the proportion of patients poten-
tially suitable for early discharge using each algorithm as an esti-
mate of efficacy.
box 1 the thrombolysis In Myocardial Infarction (tIMI) 
risk score for unstable angina or non-st elevation 
myocardial infarction9
1. Age ≥65 years
2. Three or more risk factors for coronary artery disease 
(family history of coronary artery disease, hypertension, 
hypercholesterolaemia, diabetes or being a current smoker)
3. Significant coronary artery stenosis (eg, stenosis≥50%)
4. ST-segment deviation of 0.05 mV or more on first ECG*
5. Severe angina (eg, two or more angina events in the past 
24 hours or persisting discomfort)
6. Use of aspirin in the last 7 days
7. Elevated serum cardiac markers†
Each variable=1 point.
*Patients were excluded from this analysis for all cohorts if ST-segment 
deviation was present.
†For the purpose of this analysis, serum high-sensitivity troponin levels 
for either assay were used as a binary marker low-risk versus not 
low-risk at each cut-off rather than as a cumulative addition to the TIMI 
score.
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Figure 1 Participant recruitment flow chart. *The local ethics committee for the UK site did not approve data collection for patients with ischaemia 
on initial ECG as these patients were deemed not relevant to the primary study. Aus, Brisbane, Australia; NZ, Christchurch, New Zealand; UK, 
Poole, UK; 30-Day MACE, 30-day major adverse cardiac events (death due to ischaemic heart disease, cardiac arrest, unplanned symptom-induced 
revascularisation, cardiogenic shock, ventricular arrhythmia, high-degree atrioventricular block needing intervention and acute myocardial infarction).
statistical analysis
Data were analysed using Stata V.12 and R V.3.3.2.21 Baseline 
characteristics of the study population were analysed with 
conventional group descriptive statistics. Results were pooled 
for calculation of sensitivity, specificity, negative predictive value 
(NPV) and positive predictive value for each hs-cTn assay and 
each TIMI score threshold from 0 to 2. All CIs based on the 
2×2 diagnostic matrices for each troponin assay are exact bino-
mial 95% CIs. To provide a meta-estimate of sensitivity, we used a 
random-effects bivariate model to obtain the summary estimates 
of sensitivity and its 95% CIs.22 We quantified heterogeneity 
with the I2 statistic, which reflects the proportion of variation in 
point estimates among studies beyond that expected by chance. 
I2 values <25%, 25% to <75% and ≥75% were considered to 
represent low, moderate and high heterogeneity, respectively.23
To estimate the optimal combinations of hs-cTn concentra-
tion with TIMI score to safely rule-out MACE within 30 days, 
we calculated the sensitivity and proportion low risk for every 
combination of hs-cTn from the LoD to 20 ng/L in steps of 1 ng/L 
with TIMI score from 0 to 5. To improve the generalisability 
of the estimates, we used bootstrapping, whereby we created 
500 bootstrap cohorts (replicates) and repeated the analysis on 
each cohort and averaged the resultant sensitivity, specificity 
and proportion low risk and used averaged values to construct 
contour plots of sensitivity on the TIMI score. Bootstrapping 
selects a cohort of the same size as the initial cohort by drawing 
subjects at random from the initial cohort (replacing them each 
time) and then repeating the analysis.24
resuLts
Of 5316 patients eligible for analysis, for the hs-cTnT assay, data 
were available for 3159 patients, including 704 from Australia, 
1534 from New Zealand and 921 from the UK (figure 1). Of 
these, 1866 (59.1%) were male. Mean age was 59.3 (SD 13.3) 
years and 376 (11.9%) had a 30-day MACE. For the hs-cTnI 
assay, data were available for 4532 patients, including 1761 
from Australia, 1904 from New Zealand and 867 from the 
UK (figure 1). Of these, 2964 (59.4%) were male. Mean age 
was 57.2 (SD 13.0) years and 445 (9.8%) had a 30-day MACE. 
Baseline characteristics classified by hs-cTn assay are shown in 
table 1.
Across all cohorts, 2157 and 784 patients were excluded 
because hs-cTnT and hs-cTnI results were not available, respec-
tively. There were no missing data for calculation of TIMI scores. 
No patients were lost to follow-up. Other exclusions from the 
primary studies are detailed in figure 1. Of note, 438 patients 
were excluded due to the presence of ischaemia on the initial 
ECG.
Validation of the nIce guideline
LoD of hs-cTnT and TIMI 0 strategy
Two patients (0.5%) with 30-day MACE were incorrectly classi-
fied as low risk, yielding a sensitivity of 99.5% (95% CI 98.1% 
to 99.9%) and NPV of 99.6% (98.7% to 100%) (table 2). The 
meta-estimate for sensitivity was 98.7% (96.5% to 99.6%: I2 
15.3). This strategy identified 17.9% (16.6% to 19.3%) of 
patients as low risk and potentially suitable for discharge.
LoD of hs-cTnI and TIMI 0 strategy
Five patients (1.1%) with 30-day MACE were incorrectly clas-
sified as low risk, yielding a sensitivity of 98.9% (97.4% to 
99.6%) and NPV of 99.5% (98.8% to 99.8%) (table 2). The 
meta-estimate for sensitivity was 98.5% (95.4% to 99.5%: I2 
73.7) This strategy identified 21.0% (19.9% to 22.2%) of 
patients as low risk.
The hs-cTnI assay in combination with TIMI 0 identified a 
greater proportion of patients potentially suitable for early 
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table 1 Characteristics of patients classified by high-sensitivity 
troponin assay
hs-ctnt cohort 
(n=3159)
hs-ctnI cohort
(n=4532)
Age, years; mean (SD) 59.3 (13.3) 57.2 (13.0)
Sex (% male) 1866 (59.1) 2694 (59.4)
Ethnicity (% Caucasian) 2745 (87.5)* 3917 (86.9)
Risk factors, n (%)
  Hypertension 1667 (52.8) 2233 (49.3)
  Diabetes 476 (15.1) 643 (14.2)
  Dyslipidemia 1773 (56.1) 2319 (51.2)
  Smoking current 657 (20.8) 1000 (22.1)
  Family history of CAD 1570 (49.7) 2087 (46.1)
Medical history, n (%)
  Angina 960 (30.4) 1129 (24.9)
  Myocardial infarction 734 (23.2) 916 (20.2)
  Percutaneous coronary 
intervention
544 (17.2) 701 (15.5)
  Congestive cardiac failure 162 (5.1) 175 (3.9)
  Stroke/TIA 203 (6.4) 261 (5.8)
  CABG 223 (7.1) 267 (5.9)
TIMI risk score
  Age≥65 1117 (35.4) 1322 (29.2)
  ≥3 Risk factors for coronary artery 
disease
1046 (33.1) 1344 (29.7)
  Significant coronary stenosis 907 (28.7) 1109 (24.5)
  Severe angina 951 (30.1) 1483 (32.7)
  Aspirin use in the past 7 days 1278 (40.5) 1583 (34.9)
MACE within 30 days, n (%) 376 (11.9) 445 (9.8)
*Data missing for ethnicity in 21 cases for hs-cTnT and 23 cases for hs-cTnI.
CABG,Coronary Artery Bypass Graft; CAD, Coronary Artery Disease; MACE, major 
adverse cardiac event; TIA,Transient Ischaemic Attack.
discharge; difference 3.1% (1.3% to 4.9%) in comparison to the 
hs-cTnT assay, with no difference in missed event rates; 0.6% 
(–0.9% to 2.1%).
LoD of hs-cTnT and TIMI ≤1 strategy
Four patients (1.1%) with 30-day MACE were incorrectly clas-
sified as low risk using this strategy, yielding a sensitivity of 
98.9% (97.3% to 99.7%) and NPV of 99.5% (98.8% to 99.9%) 
(table 2). The meta-estimate for sensitivity was 98.4% (95.7% to 
99.4%: I2 0). This strategy identified 28.1% (26.5% to 29.7%) 
of patients as low risk and potentially suitable for discharge.
LoD of hs-cTnI and TIMI ≤1 strategy
Seven patients (1.6%) with 30-day MACE were incorrectly 
classified as low risk, yielding a sensitivity of 98.4% (96.8% 
to 99.4%) and NPV of 99.6% (99.1% to 99.8%) (table 2). 
The meta-estimate for sensitivity was 98.2% (94.5% to 99.4: 
I2 74.4). This strategy identified 35.7% (34.3% to 37.1%) of 
patients as low risk.
The hs-cTnI assay in combination with TIMI ≤1 identified a 
greater proportion as potentially suitable for discharge; differ-
ence 7.6% (5.5% to 9.7%) in comparison to the hs-cTnT assay, 
with no difference in missed event rates; 0.5% (–1.3% to 2.3%).
LoD of hs-cTnT or I and TIMI≤2 strategy
Using either hs-cTn assay in combination with TIMI ≤2 yielded 
a meta-estimate for sensitivity for 30-day MACE of <98% 
(table 2).
early presenters
Patients presented between a median time of 2.3 hours (the UK) 
and 4.8 hours (New Zealand) after chest pain onset (online 
supplementary table 3). Subgroup analysis of patients presenting 
early (within 3 hours of chest pain onset) is included in online 
supplementary table 4.
For hs-cTnT, 1988/3159 patients (62.9%) presented early. 
The LoD of hs-cTnT and TIMI 0 strategy yielded a sensitivity of 
99.3% (97.3% to 99.9%) in this subgroup.
For hs-cTnI, 2658/4532 patients (58.6%) presented early. 
The LoD of hs-cTnI and TIMI 0 strategy yielded a sensitivity of 
99.3% (97.6% to 99.9%) in this subgroup.
Variation between sites
Characteristics of patients classified by hs-cTn assay separated by 
country are reported in the supplement (online supplementary 
table 3). The proportion of patients classified as having 30-day 
MACE ranged from 6.1% (Australia) to 15.6% (New Zealand) 
for the hs-cTnT cohort and 4.8% (Australia) to 14.6% (New 
Zealand) for hs-cTnI. The Forest plot (figure 2) demonstrates 
how the sensitivity for 30-day MACE for each strategy varied 
between countries.
exploration of 0 hour cut-off concentrations of high-
sensitivity troponin above the Lod in combination with the 
tIMI score
For hs-cTnT at presentation, the contour plot based on the 
average sensitivities of the 500 bootstrapped replicates (figure 3) 
demonstrates a high range of cut-off values (<15 ng/L) at which 
the sensitivity for 30-day MACE remains >99% in conjunction 
with a TIMI score of 0. A greater proportion of patients will be 
classified as low risk by adopting a cut-off concentration above 
the LoD (6 or 7 ng/L) in combination with a TIMI score of ≤1, 
with good sensitivity (>99%).
For hs-cTnI at presentation, the contour plot (figure 4) shows 
a narrow range of <5 ng/L in conjunction with a TIMI score of 
0 or at the LoD with a TIMI score of ≤1 where there was a very 
good sensitivity (>99%) for 30-day MACE.
dIscussIOn
Using both hs-cTn assays, with a TIMI score threshold of 0, 
the rule-out strategy advocated by NICE Guideline CG95 has 
a sensitivity of approximately 99% for 30-day MACE, a safety 
level most frequently identified by ED physicians as acceptable.25 
The proportion of patients identified as low risk (18%–21%) 
maybe sufficient to encourage change of practice. Diagnostic 
accuracy of this TIMI score threshold is maintained in early 
presenters. An additional 10%–15% of patients are identified 
as low risk if the TIMI score threshold is increased to 1. This 
is at the cost of increased numbers of false negatives, although 
the point estimate of sensitivity for both assays was >98%. 
Using a TIMI score threshold of 2, approximately 30%–40% 
of patients would be classed as low risk; however, the meta-esti-
mate for sensitivity falls to <98%. While the additional benefit 
of potentially discharging more patients early is tempting, clini-
cians should consider the lower bounds of the CIs and consider 
if they would be satisfied with the safety of the strategy if the 
true sensitivity was around this lower bound. Given the potential 
implications of missing MACE, we would encourage clinicians 
to adopt a more cautious approach. We therefore recommend 
that a TIMI score of 0 is used to identify low-risk patients, in 
combination with the LoD cut-off of either hs-cTn assay, when 
applied to clinical practice.
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table 2 Summary statistics of the suggested National Institute for Health and Care Excellence algorithm according to high-sensitivity troponin 
assay and Thrombolysis In Myocardial Infarction (TIMI) score threshold
hs-ctnt hs-ctnI
TIMI score 0 2×2 MACE No MACE MACE No MACE
  Test positive: hs-cTn>LoD or TIMI>0 374 2219 440 3140
  Test negative (rule-out): hs-cTn≤LoD and TIMI=0 2 564 5 947
Sensitivity (95% CI) 99.5% (98.1% to 99.9%) 98.9% (97.4% to 99.6%)
Meta-estimate of sensitivity (95% CI) 98.7% (96.5% to 99.6) 98.5% (95.4% to 99.5%)
Negative predictive value (95% CI) 99.6% (98.7% to 100%) 99.5% (98.8% to 99.8%)
Specificity (95% CI) 20.3% (18.8% to 21.8%) 23.2% (21.9% to 24.5%)
Positive predictive value (95% CI) 14.4% (13.1% to 15.8%) 12.3% (11.2% to 13.4%)
Proportion of patients potentially suitable for early 
discharge (95% CI)
17.9% (16.6% to 19.3%) 21.0% (19.9% to 22.2%)
TIMI score≤1 2×2 MACE No MACE MACE No MACE
  Test positive: hs-cTn>LoD or TIMI>1 372 1900 438 2477
  Test negative (rule-out): hs-cTn≤LoD and TIMI≤1 4 883 7 1610
Sensitivity (95% CI) 98.9% (97.3% to 99.7%) 98.4% (96.8% to 99.4%)
Meta-estimate of sensitivity (95% CI) 98.4% (95.7% to 99.4%) 98.2% (94.5% to 99.4%)
Negative predictive value (95% CI) 99.5% (98.8% to 99.9%) 99.6% (99.1% to 99.8%)
Specificity (95% CI) 31.7% (30.0% to 33.5%) 39.4% (37.9% to 40.9%)
Positive predictive value (95% CI) 16.4% (14.9% to 18.0%) 15.0% (13.7% to 16.4%)
Proportion of patients potentially suitable for early 
discharge (95% CI)
28.1% (26.5% to 29.7%) 35.7% (34.3% to 37.1%)
TIMI score≤2 2×2 MACE No MACE MACE No MACE
  Test positive: hs-cTn>LoD or TIMI>2 369 1736 433 2216
  Test negative (rule-out): hs-cTn≤LoD and TIMI≤2 7 1047 12 1871
Sensitivity (95% CI) 98.1% (96.2% to 99.2%) 97.3% (95.3% to 98.6%)
Meta-estimate of sensitivity (95% CI) 97.4% (94.7% to 98.8%) 97.7% (92.4% to 99.3%)
Negative predictive value (95% CI) 99.3% (98.6% to 99.7%) 99.4% (98.9% to 99.7%)
Specificity (95% CI) 37.6% (35.8% to 39.5%) 45.8% (44.2% to 47.3%)
Positive predictive value (95% CI) 17.5% (15.9% to 19.2%) 16.3% (15.0% to 17.8%)
Proportion of patients potentially suitable for early 
discharge (95% CI)
33.4% (31.7% to 35.0%) 40.5% (39.0% to 41.9%)
MACE, major adverse cardiac event; Hs-cTn: high-sensitivity cardiac troponin T or I; TIMI, thrombolysis inmyocardial infarction.
Beyond the explicit recommendations of NICE, our simu-
lation modelling demonstrates that higher cut-off concentra-
tions of both hs-cTnT and hs-cTnI may be used in combination 
with the TIMI score to identify a higher proportion of patients 
potentially eligible for early discharge with a sensitivity >99%. 
Given the higher range of cut-off values at which the sensitivity 
remains >99%, this effect is likely to be greater with the hs-cTnT 
assay. For example, a conservative threshold of around 7 ng/L in 
conjunction with TIMI 0 may enable even more patients to be 
treated as low risk than the use of the LoD alone. In this case, 
the sensitivity for 30-day MACE of hs-cTnT ≤7 ng/L and TIMI 0 
was 99.4% (99.2%–99.7%), resulting in 23.3% (22.8%–23.7%) 
of patients identified as low risk and potentially suitable for early 
discharge. Notably, in both contour graphs, even with the large 
numbers available and the bootstrapping technique used, the 
contours are not smooth and so it is appropriate to interpret 
them cautiously.
Because the LoD cut-off is both assay and manufacturer 
specific, it is important to recognise that this analysis (and the 
recommendations of NICE) applies to the specific assays tested. 
Also, the analytic reliability of the LoD as a cut-off is vulner-
able to variation in batches, set-up, calibration and operation of 
analysers in laboratories at individual sites. Therefore, expecting 
these assays to universally perform well and consistently at such 
low values may be optimistic.8
The TIMI risk score was designed to predict mortality in 
patients with confirmed ACS rather than to risk stratify undif-
ferentiated ED patients with chest pain. Consequently, the orig-
inal derivation included the variable of ST-segment deviation.9 
Irrespective of hs-cTn results and TIMI scores, in an ED environ-
ment, patients with ST-segment deviation will not be discharged. 
Ours and prior analyses have therefore classified these patients 
as high risk, yet we demonstrate that the TIMI score can still be 
successfully applied to an undifferentiated ED population.11–13 
However, given that prior analyses have demonstrated that the 
combination of the LoD cut-off and ECG testing, in the absence 
of a risk score such as TIMI, is potentially safe,5–8 the additional 
benefits of using the TIMI score remain uncertain.26
Furthermore, scores designed with the specific purpose of 
evaluating ED patients with chest pain, such as the HEART 
score,27 T-MACS rule28 or EDACS,13 may improve risk strati-
fication. Most studies evaluating risk scores are observational, 
meaning no patient is physically discharged according to the 
rule-out strategy tested. Importantly, the HEART score in combi-
nation with a single hs-cTn result has been shown to lead to no 
significant increase in early discharges compared with usual care 
within an interventional trial.29 Therefore, further data from 
interventional trials to establish the clinical and cost-effective-
ness of strategies that use a single hs-cTn result to facilitate early 
discharge are needed.
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Figure 2 Forest plots of the sensitivity (95% CI) for major adverse cardiac events occurring within 30 days separated by rule-out strategy and study 
site. FN, false negatives; FP, false positives; LoD,limit of detection; TN, true negatives; TP, true positives; TIMI, Thrombolysis In Myocardial Infarction.
Figure 3 Sensitivity contours and percentages who tested negative 
for combinations of hs-cTnT and Thrombolysis In Myocardial 
Infarction (TIMI) score. A positive test is if either the troponin or the TIMI 
score exceeds a specified value. Note that within each TIMI score the 
change in contour represent the change in sensitivity at different hs-
cTnT concentrations only.
Figure 4 Sensitivity contours and percentages who tested 
negative for combinations of hs-cTnI and Thrombolysis In Myocardial 
Infarction (TIMI) score. A positive test is if either the troponin or the TIMI 
score exceeds a specified value. Note that within each TIMI score the 
change in contour represent the change in sensitivity at different hs-cTnI 
concentrations only.
LIMItAtIOns
The processes and troponin assays used to adjudicate MACE at 
each site were not identical. While this variance may reflect the 
subjectivity of real-world clinical assessment, it is possible that 
this methodology may have led to misclassification bias.
The timing of serial troponin sampling varied across sites, with 
some patients being discharged without a 6-hour sample. It is 
possible that a small proportion of events may have been missed 
in those patients having early (2-hour) sampling. However, given 
this testing strategy was in clinical use at the time of recruitment 
and the missed event rate using this approach has been shown 
to be <0.8%,12 the impact of this methodology is likely to be 
negligible.
For this analysis, a large number of participants were excluded 
because troponin results were not available. Importantly, the 
hs-cTnT group has a higher mean age and a higher prevalence of 
comorbidities. These exclusions may therefore bias the reported 
diagnostic accuracy statistics and the proportions suitable for 
early discharge demonstrated between assays.
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cOncLusIOns
Our findings support the NICE strategy incorporating the LoD 
of hs-cTn with the TIMI score for the rule-out of ACS. The TIMI 
score threshold suggested for clinical use for identifying low-risk 
patients is 0. The optimal strategy for identifying patients suit-
able for discharge after a single hs-cTn result in combination 
with the TIMI score may include cut-off concentrations above 
the LoD.
Key questions
What is already known on this subject?
For the first time in the UK a rule-out strategy for patients 
with chest pain using a single cardiac troponin test has been 
recommended by the National Institute for Health and Care 
Excellence (NICE). NICE recommends the Thrombolysis in 
Myocardial Infarction (TIMI) risk score should be used in 
combination with a single undetectable high-sensitivity troponin 
result. However, this approach has not been validated.
What might this study add?
We assessed TIMI score thresholds for the identification of 
low-risk patients, alongside high-sensitivity cardiac troponin T 
and I assays in prospectively recruited emergency department 
patients with suspected cardiac chest pain and a non-ischaemic 
ECG from six studies, from three countries. We established a 
TIMI score threshold of 0 in combination with an undetectable 
troponin identified 18%–21% of patients potentially suitable 
for safe discharge after a single blood test with a sensitivity for 
30-day major adverse cardiac events of approximately 99%.
how might this impact on clinical practice?
Strategies that incorporate a risk score with high-sensitivity 
troponin results at presentation are ready for clinical 
implementation, yet further work is needed to define 
the optimum strategy. The strategy suggested by NICE is 
conservative and will allow early discharge of around 20% of 
patients.
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